![Cyrus Khandanpour Profile](https://pbs.twimg.com/profile_images/749291427130146821/11KrY99D_x96.jpg)
Cyrus Khandanpour
@c_khandanpour
Followers
399
Following
3K
Statuses
3K
Father, husband, Associate professor „translational cancer research“at Department of Haematology and Oncology at UKSH Campus Lübeck
Lübeck, Germany
Joined June 2016
RT @bdermanmd: Median f/u: 27 months 🦴MRD<10^-5 + CR rate: 37% [same as Isa-VRd in BENEFIT] ‼️ 39 pts completed 18 cycles. 14 (27%) d/c'd…
0
1
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Cohort study of patients w/ #MGUS (IgG, IgA, or light chain) from nationwide US Veterans Healt…
0
8
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Phase 3 CEPHEUS study of Dara+VRd vs. VRd finds MRD-negativity 60.9% for quad vs. 39.4% w/ VRd;…
0
20
0
@HDMyeloma @RaabMarc @RascheLeo @EliasKarlMai @sci_bri @KRejeski @KroenkeLab @JHillengass @marc_a_baertsch @mircoscopy @nickbolli a great event
0
0
0
RT @HDMyeloma: 📣 We are excited to announce the 10th Heidelberg Myeloma Workshop Join us on April 25–26, 2025, as international & local e…
0
12
0
RT @Amin_Turki_MD: Proud #mentor for the @EHA_Hematology 2025 #mentorship program. @young_eha fellow and mentee applications are still ope…
0
1
0
RT @MrinalPatnaik: Single-cell multiomics reveal divergent effects of DNMT3A- and TET2-mutant clonal hematopoiesis in inflammatory response…
0
10
0
RT @YanHu41082612: Super excited to share our new study from the @JD_Buenrostro Lab in @Nature! We developed a computational method for tra…
0
130
0
RT @SuyogCancer: Slide of day 1 of #GI25 . How to treat Esophageal /GEJ cancer in 2025 ? Spot on by @NiuSanford @KrishanJethwa @ASCO #GI25…
0
70
0
@Rotkreuzklinikum München GGmbH, Centrum für Hämatologie und Onkologie Bethanien. Wenn Sie an den Artikel nicht drankommen, gerne mich anschreiben.
0
0
0
RT @AhmedKo45911157: 🔬#FLT3 Inhibitors choice in #AML: Midostaurin vs. Quizartinib 📊Midostaurin: Targets FLT3-ITD & FLT3-TKD QTc <500ms Fav…
0
22
0
RT @NicoGagelmann: Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma @NEJM - reduces risk of progression to acti…
0
3
0